Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q - No Study Results Posted

Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q (MDS-LE-MON-5)

This study is currently recruiting participants.

Study NCT01081431 Information provided by Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH

First Received: March 2, 2010 Last Updated: June 24, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	March 2015
Estimated Primary Completion Date:	March 2014 (Final data collection date for primary outcome measure)